Ken Griffin Rigel Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.12 - $1.57 $457,823 - $641,770	408,771 Added 1637.38%	433,736 $641,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $16,415 - $35,566	22,799 Added 1052.59%	24,965 $36,000
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $151 - $197	142 Added 7.02%	2,166 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $58,596 - $95,218	-52,318 Reduced 96.28%	2,024 $2,000
Q1 2023 May 15, 2023	SELL	$1.25 - $2.0 $2.14 Million - $3.43 Million	-1,713,657 Reduced 96.93%	54,342 $71,000
Q4 2022 Feb 14, 2023	SELL	$0.67 - $11.9 $1.89 Million - $33.5 Million	-2,815,349 Reduced 61.43%	1,767,999 $2.65 Million
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $754,450 - $8.37 Million	685,864 Added 17.6%	4,583,348 $5.41 Million
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $47,253 - $224,981	-70,527 Reduced 1.78%	3,897,484 $4.4 Million
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $5.67 Million - $8.81 Million	2,552,290 Added 180.28%	3,968,011 $11.9 Million
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $3.01 Million - $4.56 Million	1,276,206 Added 914.74%	1,415,721 $3.75 Million
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $227,552 - $292,567	65,015 Added 87.27%	139,515 $506,000
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $9.95 Million - $14.6 Million	-3,221,586 Reduced 97.74%	74,500 $323,000
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $10.2 Million - $15 Million	-3,043,721 Reduced 48.01%	3,296,086 $11.3 Million
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $185,767 - $295,647	79,050 Added 1.26%	6,339,807 $22.2 Million
Q3 2020 Nov 16, 2020	BUY	$1.78 - $4.13 $2.98 Million - $6.91 Million	1,673,957 Added 36.5%	6,260,757 $15 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $952,980 - $1.39 Million	675,873 Added 17.28%	4,586,800 $8.39 Million
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $246,579 - $582,471	194,157 Added 5.22%	3,910,927 $6.1 Million
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $70,129 - $106,509	-43,831 Reduced 1.17%	3,716,770 $7.95 Million
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $1.02 Million - $1.64 Million	-624,480 Reduced 14.24%	3,760,601 $7.03 Million
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $623,780 - $805,973	308,802 Added 7.58%	4,385,081 $11.4 Million
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $5.7 Million - $7.55 Million	-2,848,723 Reduced 41.14%	4,076,279 $0
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $2.88 Million - $4.66 Million	1,385,846 Added 25.02%	6,925,002 $15.9 Million
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.59 $1.63 Million - $2.26 Million	-628,648 Reduced 10.19%	5,539,156 $0
Q2 2018 Aug 10, 2018	BUY	$2.83 - $4.11 $8.53 Million - $12.4 Million	3,014,348 Added 95.59%	6,167,804 $0
Q1 2018 May 11, 2018	SELL	$3.54 - $4.54 $3.24 Million - $4.16 Million	-916,086 Reduced 22.51%	3,153,456 $11.2 Million
Q4 2017 Feb 09, 2018	BUY	$3.23 - $4.3 $12.5 Million - $16.6 Million	3,871,407 Added 1953.92%	4,069,542 $15.8 Million
Q3 2017 Nov 09, 2017	BUY	$2.18 - $2.57 $431,934 - $509,206	198,135	198,135 $503,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

355K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.37B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account